Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed the day trading at $27.18 down -8.08% from the previous closing price of $29.57. In other words, the price has decreased by -$8.08 from its previous closing price. On the day, 3.71 million shares were traded. CNTA stock price reached its highest trading level at $28.59 during the session, while it also had its lowest trading level at $26.4994.
Ratios:
For a better understanding of CNTA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.57 and its Current Ratio is at 10.57. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.39.
On October 28, 2025, Stephens started tracking the stock assigning a Overweight rating and target price of $35. On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $31.Wells Fargo initiated its Overweight rating on September 03, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’25 when Accardi Mario Alberto sold 10,000 shares for $28.83 per share. The transaction valued at 288,289 led to the insider holds 178,801 shares of the business.
Accardi Mario Alberto bought 10,000 shares of CNTA for $293,000 on Dec 09 ’25. On Dec 08 ’25, another insider, Accardi Mario Alberto, who serves as the President, Orexin Program of the company, sold 10,000 shares for $30.00 each. As a result, the insider received 300,000 and left with 188,801 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 3970338816 and an Enterprise Value of 3526337280. For the stock, the TTM Price-to-Sale (P/S) ratio is 242.60 while its Price-to-Book (P/B) ratio in mrq is 12.11. Its current Enterprise Value per Revenue stands at 235.089 whereas that against EBITDA is -16.518.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.56, which has changed by 0.64031386 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $30.58, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 7.08%, while the 200-Day Moving Average is calculated to be 51.71%.
Shares Statistics:
Over the past 3-months, CNTA traded about 1.47M shares per day on average, while over the past 10 days, CNTA traded about 1438740 shares per day. A total of 134.42M shares are outstanding, with a floating share count of 88.33M. Insiders hold about 34.29% of the company’s shares, while institutions hold 59.89% stake in the company. Shares short for CNTA as of 1764288000 were 6077982 with a Short Ratio of 4.14, compared to 1761868800 on 5153546. Therefore, it implies a Short% of Shares Outstanding of 6077982 and a Short% of Float of 4.760000000000001.
Earnings Estimates
A detailed examination of Centessa Pharmaceuticals plc ADR (CNTA) is currently in progress, with 9.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.38 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.05 and -$1.42 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.63, with 11.0 analysts recommending between -$1.24 and -$2.02.
